Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chronic lymphocytic-leukemia. Found 11 abstracts

Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA. Prevention and Treatment of Cancer-Related Infections. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1412-45.   PMCID: not NIH funded
Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN. Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. Clinical Cancer Research. 2012 Mar;18(5):1395-403.   PMCID: not NIH funded
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Dec;10(12):1487-98.   PMCID: Not NIH fund
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 2005 Sep;23(9):1147-57.
Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. Familial cancer associated with a polymorphism in ARLTS1. New England Journal of Medicine. 2005 Apr 21;352(16):1667-76.
Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphorna. Haematologica. 2004 Dec;89(12):1484-91.
Smith MR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Molecular Cancer Therapeutics. 2004 Dec;3(12):1693-9.
Kraj P, Rao SP, Glas AM, Hardy RR, Milner EC, Silberstein LE. The human heavy chain Ig V region gene repertoire is biased at all stages of B cell ontogeny, including early pre-B cells. Journal of Immunology. 1997 Jun 15;158(12):5824-32.
Hardy RR, Hayakawa K. Cd5 B-Cells, a Fetal B-Cell Lineage. In: Advances in Immunology, Vol 55. 1994. p. 297-339.
Coia L, Krigel R, Hanks G, Comis R, Algazy K, Peters R, McCulloch W, Schien P. A Phase-I Study of Wr-2721 in Combination with Total-Body Irradiation (Tbi) in Patients with Refractory Lymphoid Malignancies. International Journal of Radiation Oncology Biology Physics. 1992 Jan;22(4):791-4.
Hardy RR. Variable Gene Usage, Physiology and Development of Ly-1+ (Cd5+) B-Cells. Current Opinion in Immunology. 1992 Apr;4(2):181-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chronic lymphocytic-leukemia

chronic lymphocytic-leukemia gene expression high-frequency expression b-cell lymphoma chemotherapy non-hodgkins-lymphoma phase-ii trial progression-free survival therapy maintenance rituximab utilization cytokines identification prednisone maintenance therapy final analysis bone-marrow-transplantation lymphoma pneumocystis-carinii-pneumonia herpes-simplex-virus lymphomas trial chop multiple-myeloma maintenance bcl-2 wr-2721 ly-1 b sponsored-working-group progressive multifocal vh- 1977 tbals dw-annals of internal medicine-v87-p552 patients h-chain hematopoietic stem-cells versus-host-disease new-zealand black radiation- immunoglobulin-vh- thymocytes humanized anti-cd22 antibody total body irradiation bone-marrow transplantation genes 1984 rson sl-annals of internal medicine-v100-p345 human-bone-marrow growth-factor receptor survival cooperative-oncology-group placebo-controlled trial deletions cross- t(14-18) chromosomal translocation region repertoire follicular lymphoma transgenic mice invasive pulmonary aspergillosis multicenter stem-cell transplantation 1994 lcott ja-journal of clinical oncology-v12-p107 reactive idiotype united-states cancer mantle-cell lymphoma idiotypes fetal 1994 entice hg-lancet-v343-p749 chop chemotherapy 1988 lcott ja-archives of internal medicine-v148-p2561 c-receptor polymorphisms ibritumomab tiuxetan radioimmunotherapy leukoencephalopathy autoantibodies follow-up tumor-suppressor locus high-dose therapy bendamustine region gene-expression cyclophosphamide ofatumumab lineage antibody recognize phosphatidyl choline refractory low-grade segments down-regulation metastatic breast-cancer wisconsin-oncology-network sequence non-hodgkins lymphoma alpha-interferon fludarabine-low-grade NHL advanced follicular lymphoma hepatitis-b-virus igg line wsu-fsccl immunoglobulin fusion transcript 1992 lcott ja-journal of clinical oncology-v10-p316 previously untreated red-blood-cells fetal liver advanced colorectal-carcinoma 13q14 chromosomal organization toxicity preferential rituximab term-follow-up
Last updated on Friday, January 03, 2020